Tempus AI’s Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer - Barron's

Tempus AI’s Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer

Barron's

Tempus AI’s cancer screening business is experiencing significant growth, with a 23% increase in revenue. Simultaneously, the company is making strides towards a major purchase that could further propel its advancements.